Document |
Document Title |
WO/2023/225249A1 |
Described herein are methods relating to the treatment of certain diseases with an agonist of Mfsd2A, and the treatment of certain other diseases with an inhibitor of Mfsd2A.
|
WO/2023/221892A1 |
The present invention relates to antibodies specifically binding to α-Synuclein or antigen-binding fragments thereof, a pharmaceutical composition containing the antibodies or the antigen-binding fragments thereof, a nucleic acid molecu...
|
WO/2023/225507A1 |
The disclosure provides a method of treatment for glucocorticoid excess in a patient in need thereof, comprising administering to the patient a pseudo-irreversible HSD-1 inhibitor.
|
WO/2023/224178A1 |
The present invention relates to a pharmaceutical composition and functional health food for preventing, treating, or ameliorating angiogenetic diseases, more specifically to a pharmaceutical composition comprising SHC1 protein or anti-S...
|
WO/2023/224371A1 |
The present invention relates to a composition for preventing or treating neuroinflammatory diseases comprising a novel oxadiazole derivative compound or a pharmaceutically acceptable salt thereof. The present invention has excellent act...
|
WO/2023/225506A1 |
The invention relates to synthetic RNA molecules, nucleic acid constructs comprising the same. The invention further relates to methods of using the synthetic RNA molecules such as to deliver the synthetic RNA molecule to a cell, to trea...
|
WO/2023/222858A1 |
The present invention relates to antisense oligonucleotides which are complementary to conserved TDP-43 binding sites on pre-mRNA transcripts, which are capable of restoring RNA binding protein function in the processing of multiple inde...
|
WO/2023/225206A1 |
Disclosed herein are methods and compositions for treating a demyelinating disease, such as multiple sclerosis, by administering to a subject suffering the disease a combination of at least one muscarinic receptor antagonist and at least...
|
WO/2023/220365A1 |
Described in certain example embodiments herein are methods of and compositions for treating a CASK-linked neurodevelopmental disorder. In certain example embodiments, the method includes administering, to a subject in need thereof, an a...
|
WO/2023/218868A1 |
This sympathetic nerve activator contains a compound represented by structural formula (1).
|
WO/2023/219511A1 |
The invention relates to combination or composition comprising: (i) nicotinic acid or a derivative thereof, and (ii) a fatty acid or a derivative thereof selected from tetradecylthioacetic acid 5 (TTA) or a derivative thereof. The invent...
|
WO/2023/220439A1 |
Described herein are compounds that modulate splicing of a pre-mRNA, encoded by genes, and methods of treating diseases and conditions associated with gene expression or activity of proteins encoded by genes.
|
WO/2023/220433A1 |
Described herein are compounds that modulate splicing of a pre-mRNA, encoded by genes, and methods of treating diseases and conditions associated with gene expression or activity of proteins encoded by genes.
|
WO/2023/220367A1 |
The invention relates to a method of treating or preventing a disease or condition comprising administering a therapeutically effective amount of a psychedelic compound to a patient by intramuscular injection. Uses, formulations and kits...
|
WO/2023/218195A1 |
The invention provides compounds of formula (I) Wherein the substituents are as set out in further detail in the specification. The compounds are potent inhibitors of GCN2 and they have excellent pharmacokinetic properties. The compounds...
|
WO/2023/219227A1 |
The administration of a composition of the present invention can suppress the accumulation of amyloid beta, leading to effective prevention, alleviation, or treatment of amyloidopathies, such as Alzheimer's disease.
|
WO/2023/220058A1 |
Disclosed are therapeutic methods for reducing the rate of functionality loss in patients suffering from amyotrophic lateral sclerosis (ALS) during the accelerated stages of this disease.
|
WO/2023/219939A1 |
The present disclosure relates to compounds and methods for modulating the expression of fxn, and treating diseases and conditions in which fxn plays an active role.
|
WO/2023/220084A1 |
Described herein, in part, are methods useful for preventing and/or treating a disease or condition relating to aberrant function or activity of a T-type calcium channel, such as psychiatric disorders (e.g., mood disorder (e.g., major de...
|
WO/2023/218023A1 |
The present invention relates to compounds of the formula (I) Formula (I) wherein Ar1, R1, R2, R3, X1, X2, Y, and Z are as described in the description, to their preparation, to pharmaceutically 5 acceptable salts thereof, and to their u...
|
WO/2023/217020A1 |
Disclosed in the present invention are an immunoglobulin κ-type light chain (Vκ4-1-IgLC) polypeptide having a unique Vκ4-1 and the use thereof. The amino acid sequence of the Vκ4-1-IgLC polypeptide is as shown in SEQ ID NO.1, and the...
|
WO/2023/219468A1 |
The present invention relates to a composition comprising dopamine-hyaluronic acid for treating Parkinson's disease and, particularly, to a therapeutic composition for supplying dopamine to nerve cells as a dopamine mimic. The compositio...
|
WO/2023/218364A1 |
The present invention provides an anti-aging and anti-inflammatory composition comprising nicotinamide mononucleotide (NMN) or an analog thereof, and certain antioxidants, more specifically resveratrol and at least of ergothioneine and h...
|
WO/2023/220366A1 |
The invention relates to a method of treating or preventing a disease or condition comprising administering a therapeutically effective amount of a psychedelic compound to a patient by subcutaneous injection. Uses, formulations and kits ...
|
WO/2023/215984A1 |
The present application includes a composition comprising a non-racemic mixture R-1,3-butanediol and S-1,3-butanediol, wherein the R-1,3-butanediol is present in the composition in a greater amount by enantiomeric equivalents, relative t...
|
WO/2023/218187A1 |
Disclosed are heterobifunctional compounds that can induce the degradation of leucine-rich repeat kinase 2 (LRRK2) and PDE6D. These compounds can engage LRRK2 on one end and bind to an ubiquitin E3 ligase (e.g. cereblon, Von Hippel-Linda...
|
WO/2023/219164A1 |
This pharmaceutical is used in a method including a step A for administering a bubble to a mammal and irradiating a target region in the mammal with ultrasound, and a step B for administering a composite to the mammal. The pharmaceutical...
|
WO/2023/219140A1 |
An inhibitory neuron-specific promoter sequence is discovered, which has a shorter length compared with a mGAD65 promoter and is not deteriorated in all of a promoter activity, specificity to an inhibitory neuron and a gene expression ef...
|
WO/2023/220370A1 |
This disclosure relates to the field of therapeutic tyrosine kinase inhibitors, in particular, Bruton tyrosine kinase ("BTK") inhibitors, for treatment of subjects with myelin oligodendrocyte glycoprotein antibody disease (MOGAD).
|
WO/2023/218453A1 |
Provided are methods of treating a subject having a disease associated with a polyalanine expansion mutation, by administering to the subject a therapeutically effective amount of an agent capable of upregulating expression or activity o...
|
WO/2023/220287A1 |
Provided herein are targeting peptides and vectors containing a sequence that encodes the targeting peptides that deliver agents to specific substructures in the brain. Specifically, the targeting peptide is a component of a modified, se...
|
WO/2023/217112A1 |
Use of a mesenchymal stem cell in the preparation of a drug for treating depression. The mesenchymal stem cell is a mesenchymal stem cell of the dental pulp, such as a dental pulp stem cell from human exfoliated deciduous teeth.
|
WO/2023/218869A1 |
A parasympathetic nerve activator comprising a compound represented by structural formula (1).
|
WO/2023/220381A1 |
Methods of preparation of lysergic acid and derivatives thereof. Methods of using lysergic acid and derivatives thereof, such as methods of treating neurodegenerative disorders. Derivatives of lysergic acid and pharmaceutically acceptabl...
|
WO/2023/219406A1 |
An anti-chitinase-3-like protein 1 antibody or antigen-binding fragment thereof of the present invention comprises a light chain variable region comprising CDRs of table 1 and a heavy chain variable region comprising CDRs of table 2.
|
WO/2023/219533A1 |
The present invention relates to biotechnology. Described is a recombinant adeno-associated vector rAAV based on the serotype AAV.PHP.B and containing a polynucleotide that encodes the survival motor neuron (SMN) protein, said vector bei...
|
WO/2023/220236A1 |
Provided herein are methods for treating at least one symptom of ALS in a subject who has received a first dosage of BSEP inhibitor, the method including administering to the subject a composition comprising a bile acid or a pharmaceutic...
|
WO/2023/220408A1 |
Compounds are provided for modulating NLRP3 inflammasome generally, or for treating a NLRP3 inflammasome dependent condition more specifically, by contacting the NLRP3 inflammasome or administering to a subject in need thereof, respectiv...
|
WO/2023/217192A1 |
The present invention provides preparation of a chimeric antigen receptor immune cell constructed based on an MSLN precursor protein and use thereof. Specifically, the present invention provides a chimeric antigen receptor (CAR) modified...
|
WO/2023/220363A1 |
The invention relates to a method of treating or preventing a disease or condition comprising administering a therapeutically effective amount of a psychedelic compound to a patient by intravenous infusion. Uses, kits, formulations and d...
|
WO/2023/217437A1 |
This application includes methods for reducing axonal tau protein. Those methods include inhibiting the binding between MAPT mRNA and hnRNP R.
|
WO/2022/261422A9 |
The invention features panels of genes associated with Sudden Unexpected Death in Pediatrics (SUDP), and methods of using such panels to identify a cause of death, and to select children at risk of SUDP for therapies to treat pathologies...
|
WO/2023/218100A1 |
This invention relates to therapeutic, diagnostic and/or prophylactic formulations and dosages and dosing regimens of anti-CD3 antibodies, as well as to methods for using such formulations and dosages and dosing regimens.
|
WO/2023/219394A1 |
The present invention provides a mutated human SMN1 protein, a polynucleotide encoding same, and a pharmaceutical composition for treating spinal muscular atrophy, comprising a vector loading same. The composition lowers liver toxicity s...
|
WO/2023/220435A1 |
Described herein are compounds that modulate splicing of a pre-mRNA, encoded by genes, and methods of treating diseases and conditions associated with gene expression or activity of proteins encoded by genes.
|
WO/2023/219548A1 |
The invention relates to a combination comprising an effective amount of varenicline, or a salt thereof, and an effective amount of a glycine transport (GlyT) inhibitor. This combination achieves a selective dopamine increase in ventral ...
|
WO/2023/219991A1 |
Methods of treating sleep apnea and snoring comprising administering ampreloxetine or a pharmaceutically acceptable salt thereof, optionally as a monotherapy, or optionally in combination with a muscarinic receptor antagonist (MRA) or a ...
|
WO/2023/217675A1 |
To meet the needs of new therapies for preventing or treating pathological dysbiosis of the intestinal microbiota, in particular for treating or preventing neurodegenerative or intestinal diseases. The invention relates to the use of com...
|
WO/2023/216753A1 |
The present invention relates to an imidazopyridazine derivative, and a preparation method therefor, a pharmaceutical composition thereof and the use thereof. Provided in the present invention are a compound as represented by formula (1)...
|
WO/2023/216299A1 |
Provided is use of a circular ribonucleic acid translation protein in the field of depression diagnosis and treatment. A circRNA isomer of FKBP38 is confirmed by means of an immunoblotting experiment to have translation ability, a protei...
|